We are live on ! Find out more
MVM

Medicxi Ventures Management Portfolio holdings

AUM $982M
1-Year Est. Return 210.17%
This Fund
S&P 500
This Quarter Est. Return
+14.08%
1 Year Est. Return
+210.17%
3 Year Est. Return
+787.54%
5 Year Est. Return
+404.19%
10 Year Est. Return
AUM
$835M
AUM Growth
+$90.6M
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
5
New
Increased
Reduced
Closed

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CNTA
1
DELISTED
Centessa Pharmaceuticals
CNTA
$499M 59.8%
19,963,157
PHAT icon
2
Phathom Pharmaceuticals
PHAT
$708M
$124M 14.83%
7,464,572
NAMS icon
3
NewAmsterdam Pharma
NAMS
$3.25B
$101M 12.06%
2,869,565
RAPT
4
DELISTED
RAPT Therapeutics
RAPT
$94.6M 11.33%
2,794,000
AURA icon
5
Aura Biosciences
AURA
$725M
$16.6M 1.98%
3,039,892

Similar funds

Medicxi Ventures Management's Q4 2025 Portfolio in Review

As of Q4 2025, Medicxi Ventures Management held 5 positions worth $835M, up 12% from $744M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q4 2025: portfolio turnover was 0%. Medicxi Ventures Management opened no new positions and made no exits, leaving the 5-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Medicxi Ventures Management's ten largest holdings make up 100% of its $835M portfolio in Q4 2025.
  • Medicxi Ventures Management opened 0 new positions and closed 0 in Q4 2025.
  • Medicxi Ventures Management's portfolio value rose 12% quarter-over-quarter to $835M.

Based on Medicxi Ventures Management's 13F filing for Q4 2025, filed 23 Jan 2026.